

NCCN Thyroid Carcinoma V.1.2011 – Follow-up – December 16, 2010

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
<p>PAP-6, FOLL-5, HÜRT-5, MEDU-5</p> <p>Internal request: Should denosumab be added as a treatment option for patients with bone metastases?</p>	<p>Based upon the FDA prescribing information and abstract data for denosumab, the panel consensus was to add denosumab to the Papillary, Follicular, Hürthle cell, and Medullary carcinoma guidelines as a treatment option to consider for patients with bone metastases.</p>	<ul style="list-style-type: none"> Prescribing information for denosumab: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125320s0071bl.pdf Henry DH, von Moos R, Hungria V, et al. Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advanced cancer [abstract]. J Clin Oncol 2010;28(Suppl 15):Abstract 9133. http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9133. 	13	2	4